Draft:Shalabh Gupta
 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Ponyo (talk | contribs) 3 months ago. (Update) |
Shalabh Gupta, MD | |
|---|---|
| Nationality | Indian American |
| Alma mater | New York University |
| Occupation(s) | Physician and entrepreneur |
| Known for | Unicycive Therapeutics |
Shalabh Gupta, MD is an Indian-American physician and entrepreneur. He is the founder and CEO of Unicycive Therapeutics, a biopharmaceutical company.
Life and career[edit]
Gupta earned his MD from Jawaharlal Institute of Postgraduate Medical Education & Research in India. In 1999, he graduated with a Master's in Public Administration (MPA) in Health Care Finance and Management from New York University.
From 2004 to 2008, Gupta served as an attending physician at New York University (NYU) Medical Center and held a clinical faculty position at the NYU School of Medicine. [1][2]
During the early part of his career he served in different roles. Gupta worked as a medical advisor to Synageva and a commercial strategist at Genentech. Additionally, he also worked as an equity researcher covering US pharmaceutical companies at UBS Investment Bank, and also worked as an equity researcher covering biotechnology companies at Rodman & Renshaw.[3]
BioCycive[edit]
In 2011, Gupta founded BioCycive, a biotechnology company focused on oncology.
Globavir[edit]
In 2013, Gupta founded Globavir, a therapeutics and diagnostics company.[4][5][6]
Unicycive Therapeutics[edit]
In August 2016, Gupta founded Unicycive Therapeutics, a biopharmaceutical company involved in the research and development of treatment for kidney diseases.[7][8][9][10]
Since 2020, Gupta serves as an advisor to the UCSF Innovation Center. He previously served on the Beall Center for Innovation and Entrepreneurship board of directors at the Paul Merage School of Business, University of California Irvine.[3]
Gupta serves as an advisor to the UCSF Innovation Center and has been an advisor to SPARK at Stanford University School of Medicine since 2012.[3]
References[edit]
- ^ "Shalabh Gupta, MD". Unicycive. Retrieved 2024-01-08.
- ^ "Doctor to IPO: How Shalabh Gupta Became a Biotech Entrepreneur". Founders Network. Retrieved 2024-01-08.
- ^ a b c https://www.linkedin.com/in/shalabhgupta/
- ^ "Shalabh Gupta : Positions, Relations and Network - MarketScreener". ca.marketscreener.com. Retrieved 2024-01-08.
- ^ "Shalabh Gupta, MD - Founder & CEO at Unicycive Therapeutics". THE ORG. Retrieved 2024-01-08.
- ^ "Traders News Source Interviews Dr. Shalabh Gupta, CEO at Unicycive Therapeutics, Inc". Yahoo Finance. 2022-05-24. Retrieved 2024-01-08.
- ^ "Shalabh Gupta, Unicycive Therapeutics Inc: Profile and Biography". Bloomberg.com. Retrieved 2024-01-08.
- ^ Network, Founders (2022-12-12). "Doctor to IPO: How Shalabh Gupta Became a Biotech Entrepreneur". Founders Network. Retrieved 2024-01-08.
- ^ "Unicycive Therapeutics, Inc. CEO, Shalabh Gupta on how they are Bringing Innovation to Treatments for Kidney Diseases". EIN News. 2022-10-06. Retrieved 2024-01-08.
- ^ "Unicycive Therapeutics Inc - Company Profile and News". Bloomberg.com. Retrieved 2024-01-08.